McKesson Co. (NYSE:MCK) Stock Holdings Trimmed by Sanctuary Advisors LLC

Sanctuary Advisors LLC decreased its holdings in McKesson Co. (NYSE:MCK) by 0.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 28,236 shares of the company’s stock after selling 251 shares during the quarter. Sanctuary Advisors LLC’s holdings in McKesson were worth $17,071,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of MCK. MidAtlantic Capital Management Inc. bought a new stake in shares of McKesson during the 3rd quarter worth about $29,000. RPg Family Wealth Advisory LLC bought a new position in shares of McKesson in the third quarter valued at approximately $31,000. Synergy Asset Management LLC acquired a new position in shares of McKesson during the fourth quarter valued at approximately $32,000. Crews Bank & Trust bought a new stake in McKesson during the fourth quarter worth approximately $33,000. Finally, Bruce G. Allen Investments LLC lifted its position in McKesson by 51.9% in the fourth quarter. Bruce G. Allen Investments LLC now owns 82 shares of the company’s stock worth $47,000 after purchasing an additional 28 shares during the period. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson Stock Down 1.4 %

MCK opened at $593.82 on Tuesday. The firm has a market capitalization of $75.38 billion, a P/E ratio of 27.19, a PEG ratio of 1.30 and a beta of 0.52. The stock has a fifty day moving average of $587.26 and a 200-day moving average of $562.38. McKesson Co. has a 12-month low of $464.42 and a 12-month high of $637.51.

McKesson (NYSE:MCK) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $8.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. On average, analysts expect that McKesson Co. will post 32.69 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Monday, March 3rd will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 0.48%. The ex-dividend date is Monday, March 3rd. McKesson’s payout ratio is presently 13.00%.

Insider Buying and Selling at McKesson

In other news, EVP Leann B. Smith sold 579 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $572.79, for a total value of $331,645.41. Following the transaction, the executive vice president now directly owns 864 shares of the company’s stock, valued at approximately $494,890.56. This represents a 40.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders have sold 1,346 shares of company stock worth $795,275. 0.11% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

MCK has been the topic of several research analyst reports. Bank of America lowered their price target on McKesson from $680.00 to $650.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Mizuho initiated coverage on McKesson in a report on Wednesday, December 4th. They set a “neutral” rating and a $630.00 target price on the stock. Baird R W raised shares of McKesson from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 7th. Citigroup lowered their price objective on shares of McKesson from $713.00 to $677.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Finally, Morgan Stanley increased their target price on shares of McKesson from $612.00 to $642.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. Two investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $645.79.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.